NCT07063316

SGLT2 Inhibitors and Renal Anemia in Japan: RWD

Effect of SGLT2 Inhibitors on Renal Anemia and Its Management in Patients With CKD in Japan

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 15,000 (estimated)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objectives of the study are: 1. To compare the risk and timing of anemia onset between Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitor users and non-users in patients with chronic kidney disease (CKD) from the index date to first event occurrence or the end date of each individual's follow-up. 2. To compare the following outcomes from the index date to 731 days (24 months) or the end date of each individual's follow-up: A) Longitudinal changes in laboratory values between SGLT2 inhibitor users and non-users in patients with CKD. B) Prescription patterns and treatment regimens for anemia between SGLT2 inhibitor users and non-users in patients with CKD, including analysis of medication types, dosing strategies, and duration of treatments. C) Anemia-related healthcare costs between SGLT2 inhibitor users and non-users.

Conditions

• Chronic Kidney Disease

Interventions

Type	Name	Description
DRUG	SGLT2 inhibitor	SGLT2 inhibitor

Timeline

• Start date: 2025-07-23
• Primary completion: 2026-09-30
• Completion: 2026-09-30
• First posted: 2025-07-14
• Last updated: 2026-03-04

Locations

1 site across 1 country: Japan